AI in Diagnostics: Where It Helps — and Where the Caribbean Must Be Careful

Artificial intelligence is rapidly entering diagnostic workflows across global health systems. In radiology, pathology, ophthalmology, dermatology, and triage, AI tools promise faster interpretation, earlier detection, and more consistent decision-making.

In the Caribbean, where specialist shortages are chronic and diagnostic delays carry outsized consequences, this promise is especially compelling.

Consider a mid-sized public hospital in the region facing a familiar constraint: one radiologist covering an entire island’s CT scans and mammograms, with turnaround times stretching from days to weeks. An AI vendor proposes a triage tool that flags suspected pulmonary embolisms and high-risk breast lesions within minutes of image acquisition. The pitch is straightforward: shorten delays, reduce missed findings, extend scarce expertise.

The appeal is obvious.

But AI in diagnostics is not a shortcut to capacity. It is an amplifier — of both strengths and weaknesses. Whether it improves care or introduces new risk depends less on the algorithm and more on how the system absorbs it.

The Caribbean Diagnostic Context Matters

Diagnostic bottlenecks in the Caribbean are structural, not incidental. Limited access to sub-specialists, reliance on overseas interpretation, uneven imaging and laboratory capacity, and long turnaround times all shape patient outcomes.

In our hypothetical hospital, the AI tool may flag urgent cases within minutes — but the radiologist is still one person. If flagged scans double because the model errs on the side of sensitivity, review capacity becomes even more strained. If confirmatory biopsies require overseas referral, faster identification may not translate into faster treatment.

AI addresses interpretation. It does not automatically resolve infrastructure, workforce, or referral constraints.

If the surrounding system cannot absorb faster or more frequent diagnostic signals, AI adds noise rather than value.

Where AI Can Genuinely Help

When deployed with discipline, AI can meaningfully strengthen diagnostic systems in small states.

Triage and Prioritisation

In the hospital example, the AI tool flags high-risk chest scans for immediate review. The radiologist now sees suspected embolisms first instead of scanning a long queue chronologically. This does not replace human expertise; it sorts demand intelligently in a context where review capacity is limited.

Used carefully, triage reduces harm from delay.

The tool supports judgment. It does not override it.

Decision Support, Not Decision Replacement

The same AI model offers probability estimates and highlights regions of concern. For generalist physicians reviewing images overnight — common in small systems — this second-read support reduces variability and increases confidence.

The tool supports judgment. It does not override it.

Quality Assurance and Audit

Over several months, administrators notice that the AI tool consistently flags subtle findings that were previously missed in retrospective review. Rather than triggering blame, the hospital uses this signal to improve protocols and peer review processes.

In small systems, such feedback loops can meaningfully elevate quality — provided governance encourages learning rather than punishment.

Where AI Fails — Predictably

Many AI deployments fail not because the models are fundamentally flawed, but because systems overestimate readiness.

In our hospital, the AI tool was trained primarily on North American datasets. When applied locally, false positives increase among patients with different comorbidity patterns. Data quality issues — inconsistent imaging protocols, incomplete records — further degrade performance.

Failure is rarely dramatic. It is gradual erosion of trust.Failure is rarely dramatic. It is gradual erosion of trust.

Meanwhile, accountability is unclear. If the AI flags a lesion and the radiologist disagrees, who prevails? If the AI misses a finding later detected clinically, is the error attributed to the clinician or the tool?

An AI output that sits outside formal medical records or referral pathways does not improve care. It introduces ambiguity.

Failure is rarely dramatic. It is gradual erosion of trust.

Data Bias Is Not Theoretical Here

Most commercial AI diagnostic tools are trained on datasets drawn largely from North America, Europe, or East Asia. Caribbean populations — shaped by distinct genetic ancestry, environmental exposures, and disease profiles — are often underrepresented.

In our example, the AI model performs well on standard mammography cases but struggles with denser breast tissue patterns more prevalent in certain subpopulations. False reassurance in some cases, false alarms in others.

Without local validation, bias is not hypothetical. It is statistical inevitability.

Regions already managing inequities cannot afford to import tools that quietly reproduce them.

Accountability Cannot Be Outsourced to Algorithms

In the hospital board meeting following implementation, a simple question emerges: if the AI flags a high-risk scan that is not escalated, who is responsible? The radiologist? The hospital? The vendor?

Ambiguity discourages adoption. Clinicians either over-rely on the tool to reduce personal risk or underuse it to avoid liability exposure.

Clear governance is not optional. AI must operate within explicit clinical and regulatory frameworks that define its role, limitations, and oversight.

Clear governance is not optional. AI must operate within explicit clinical and regulatory frameworks that define its role, limitations, and oversight.

Without that clarity, experimentation becomes risk accumulation.

AI Is Only as Good as the Pathway It Feeds Into

Suppose the AI tool successfully increases early detection of suspicious breast lesions. But biopsy slots remain limited. Oncology consultations are booked months out. Treatment capacity is constrained.

Faster diagnosis without expanded follow-up capacity creates new ethical strain. Patients are told earlier that something may be wrong — without the system’s ability to respond proportionately.

AI can accelerate identification. It cannot manufacture capacity.

Deployment must therefore be selective and sequenced. Interpretation gains should align with downstream readiness.

AI can accelerate identification. It cannot manufacture capacity.

The Temptation to Leapfrog — and Why It’s Risky

There is increasing pressure on small states to “leapfrog” traditional system development using AI. The narrative is attractive: bypass incremental reform and jump directly to advanced diagnostic capability.

In practice, leapfrogging without foundations magnifies fragility.

If the hospital’s medical record system is fragmented, AI outputs may not integrate seamlessly. If referral pathways are unclear, flagged findings create confusion rather than coordination. If workforce structures are under-resourced, implementation fatigue sets in quickly.

AI does not replace weak data foundations, fragmented records, unclear referral pathways, or workforce gaps. It exposes them.

Sophistication layered on fragility remains fragility.

What Responsible AI Adoption Requires Now

For Caribbean health systems, responsible AI in diagnostics demands disciplined choices.

AI in diagnostics can be transformative for Caribbean health systems — but only when treated as clinical infrastructure rather than innovation theatre.

Use-case discipline ensures deployment targets genuine bottlenecks with viable pathways.

Local validation tests performance against Caribbean data before scale.

Workflow integration ensures outputs live within clinical records and referral systems.

Clear accountability rules define how AI informs — but does not replace — professional judgment.

Continuous evaluation monitors performance over time rather than assuming initial accuracy persists.

In our hospital example, the AI triage tool ultimately succeeds — not because it was cutting-edge, but because leadership limited its scope, validated it locally, integrated it carefully, and aligned it with available follow-up capacity.

The technology was not transformative on its own.

The discipline around it was.

AI in diagnostics can be transformative for Caribbean health systems — but only when treated as clinical infrastructure rather than innovation theatre.

Used carefully, AI extends scarce expertise and improves consistency. Used carelessly, it introduces new risk into already constrained environments.

The question is not whether AI will enter Caribbean diagnostic workflows.

It already has.

The question is whether systems will integrate it with the operational discipline required to make it safe, equitable, and genuinely useful.